Cancer Research Matters is a new podcast from Cancer Research UK featuring some of the incredible researchers behind cancer research.
Cancer Research Matters provokes conversation around cancer science, how it shapes our understanding of the disease and the challenges we face as we develop therapies.
The first series focusses on the 20th anniversary of CRUK – we’ll be winding back the clock on some of the great discoveries and breakthroughs made in the past two decades and asking some leading names where they think we’ll be in another 20 years.
The episode features Steve Jackson. Steve is the University of Cambridge Frederick James Quick Professor of Biology. He is also Head of Cancer Research UK Laboratories at the Wellcome Trust/Cancer Research UK Gurdon Institute. Steve’s main academic work is in the field of DNA damage repair, but he also founded KuDOS Pharmaceuticals in order to translate and market the PARP inhibitor Olaparib/ Lynparza. He talks about the difference between academic and commercial science, tips for forming a spinout company and what we should aim for in the next 20 years of cancer research.
If you’d rather listen via the podcast site – click here
Further reading on the commercialisation of DNA repair inhibitors: